[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335957-105":59,"doc-detail-335957-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","who-can-benet-from-postmastectomy-radiotherapy-among-hrher2-t1-2-n1m0-breast-cancer-patients-an-explainable-machine-learning-mortality-prediction-based-approach","Who can beneﬁt from postmastectomy radiotherapy among HR+/HER2-T1-2 N1M0 breast cancer patients? - An explainable machine learning mortality prediction based approach","","The necessity of postmastectomy radiotherapy (PMRT) for patients with HR+/HER2-T1-2 N1M0 breast cancer remains controversial. This study applies explainable machine learning to learn patient feature importance and to identify subgroups that may benefit from PMRT, while providing decision-support guidance for clinicians. Two survival models—a deep learning neural network and a Cox proportional hazards model—were trained and validated using SEER patients from 2013–2018, with performance evaluated by c-index and interpretability via global and individual feature importance.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/who-can-benet-from-postmastectomy-radiotherapy-among-hrher2-t1-2-n1m0-breast-cancer-patients-an-explainable-machine-learning-mortality-prediction-based-approach/335957/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/who-can-benet-from-postmastectomy-radiotherapy-among-hrher2-t1-2-n1m0-breast-cancer-patients-an-explainable-machine-learning-mortality-prediction-based-approach/335957.png","ImageObject",300,407,{"name":92,"@type":93},"Patrick","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main objective of this study on PMRT?","Question",{"text":112,"@type":113},"To use explainable machine learning to identify which patient subgroups with HR+/HER2-T1-2 N1M0 breast cancer may benefit from postmastectomy radiotherapy and to derive features that influence outcomes for clinical guidance.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which machine learning survival models were trained and validated?",{"text":117,"@type":113},"The study trained and validated two survival models: a deep learning neural network and a Cox proportional hazards model.",{"name":119,"@type":110,"acceptedAnswer":120},"How was survival model performance assessed, and what validation strategy was used?",{"text":121,"@type":113},"Performance was assessed using the concordance index (c-index). The models were evaluated on an internal test dataset and also externally validated.",{"name":123,"@type":110,"acceptedAnswer":124},"What patient groups were concluded to benefit from PMRT?",{"text":125,"@type":113},"Patients with tumor size >14 mm and age older than 54, and a cohort with tumor size >14 mm and grade worse than well-differentiated, were concluded to benefit from PMRT.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},335957,1790156069,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":143,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":144,"faqs":145,"seo_title":146,"seo_description":67,"update_tm":147,"read_time":148,"preview_page_count":4},549758146520,"https://ap-avatar.wpscdn.com/avatar/80002397d8c0411e94?_k=1775819394049821470","TYPE Original Research PUBLISHED 02 February 2024 DOI 10.3389/fendo.2024.1326009  \nOPEN ACCESS  \nEDITED BY  \nChirag Patel,  \nNational Cancer Institute at Frederick (NIH), United States  \nREVIEWED BY Ankita Singh,  \nIndian Council of Agricultural Research, India Yogesh Kumar,  \nUniversity Medical Center HamburgEppendorf, Germany  \n*CORRESPONDENCE Fei Cao  \n [673893622@qq.com](673893622@qq.com)  \n†These authors have contributed equally to this work  \nRECEIVED 22 October 2023  \nACCEPTED 10 January 2024  \nPUBLISHED 02 February 2024  \nCITATION  \nJin L, Zhao Q, Fu S, Zhang Y, Wu S, Li X and Cao F (2024) Who can beneﬁt from postmastectomy radiotherapy among HR +/HER2-T1-2 N1M0 breast cancer patients? An explainable machine learning mortality prediction based approach.  \nFront. Endocrinol. 15:1326009 .  \ndoi: 10.3389/fendo.2024.1326009  \nCOPYRIGHT  \n© 2024 Jin, Zhao, Fu, Zhang, Wu, Li and Cao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nWho can beneﬁt from postmastectomy radiotherapy among HR+/HER2-T1-2 N1M0 breast cancer patients? An explainable machine learning mortality prediction based approach  \nLong Jin 1†, Qifan Zhao 2†, Shenbo Fu 3, Yuan Zhang 4, Shuhan Wu 5, Xiao Li 6 and Fei Cao 4*  \n1 Department of Radiation Oncology, Shaanxi Provincial People’s Hospital, Xi’an, China, 2 Department of Computer Science, The University of Hong Kong, Hong Kong, Hong Kong SAR, China,  \n3 Department of Radiation Oncology, Shaanxi Provincial Cancer Hospital, Xi’an, China, 4 Department of Oncology, Shaanxi Provincial People’s Hospital, Xi ’an, China, 5 Department of Surgical Oncology, Shaanxi Provincial People’s Hospital, Xi’an, China, 6 Internal Medicine, St. Luke's Hospital, Chesterﬁeld, MO, United States  \nObjective: The necessity of postmastectomy radiotherapy(PMRT) for patients with HR+/HER2 T1-2 N1M0 breast cancer remains controversial. We want to use explainable machine learning to learn the feature importance of the patients and identify the subgroup of the patients who may beneﬁt from the PMRT. Additionally, develop tools to provide guidance to the doctors.  \nMethods: In this study, we trained and validated 2 machine learning survival models: deep learning neural network and Cox proportional hazard model. The training dataset consisted of 35,347 patients with HR+/HER2-T1-2 N1M0 breast cancer who received mastectomies from the SEER database from 2013 to 2018 .  \nThe performance of survival models were assessed using a concordance index (c-index).Then we did subgroup analysis to identify the subgroup who could beneﬁt from PMRT. We also analyzed the global feature importance for the model and individual feature importance for individual survival prediction. Finally, we developed a Cloud-based recommendation system for PMRT to visualize the survival curve of each treatment plan and deployed it on the Internet.  \nResults: A total of 35,347 patients were included in this study. We identiﬁed that radiotherapy improved the OS in patients with tumor size >14mm and age older than 54: 5-year OS rates of 91 . 9 versus 87 . 2%(radio vs. nonradio, P \u003C0 . 001) and cohort with tumor size >14mm and grade worse than well-differentiated, 5-year OS rates of 90 . 8 versus 82 .3%(radio vs. nonradio, P \u003C0 . 001) .The deep learning network performed more stably and accurately in predicting patients survival than the random survival forest and Cox proportional hazard model on the internal test dataset (C-index=0 .776 vs 0 . 641) and in the external validation(Cindex=0.769 vs 0.650). Besides, the deep learning model identiﬁed several key factors that signiﬁcantly ","cbCaieEl6BkXQ1J2","https://ap.wps.com/l/cbCaieEl6BkXQ1J2","pdf",1961068,"English","# Objective\n# Methods\n# Results\n# Conclusion\n# Keywords\n# 1 Introduction","[{\"question\":\"What is the main objective of this study on PMRT?\",\"answer\":\"To use explainable machine learning to identify which patient subgroups with HR+/HER2-T1-2 N1M0 breast cancer may benefit from postmastectomy radiotherapy and to derive features that influence outcomes for clinical guidance.\"},{\"question\":\"Which machine learning survival models were trained and validated?\",\"answer\":\"The study trained and validated two survival models: a deep learning neural network and a Cox proportional hazards model.\"},{\"question\":\"How was survival model performance assessed, and what validation strategy was used?\",\"answer\":\"Performance was assessed using the concordance index (c-index). The models were evaluated on an internal test dataset and also externally validated.\"},{\"question\":\"What patient groups were concluded to benefit from PMRT?\",\"answer\":\"Patients with tumor size \\u003e14 mm and age older than 54, and a cohort with tumor size \\u003e14 mm and grade worse than well-differentiated, were concluded to benefit from PMRT.\"}]","Who can beneﬁt from postmastectomy radiotherapy among HR+/HER2-T1-2 N1M0 breast cancer patients? - An explainable machine learning mortality prediction based approach | PDF",1790012937,25]